Call to be held on Tuesday, May 26th at 11:00am EDT WOODCLIFF LAKE, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced… Read More..

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020. Dr. Feltner joins Exicure from AveXis (now part of Novartis) where he was the… Read More..

- Trading under "TMBR" on the NYSE American Market to begin May 19, 2020 - Closed $25 million financing WOODCLIFF LAKE, N.J., May 18, 2020 /PRNewswire/ -- Timber Pharmaceuticals, Inc., (NYSE American: TMBR), formerly known as BioPharmX Corporation ("Timber" or the "Company"), a biopharmaceutical company focused on the development and… Read More..